<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-635
Date of Submission: 2024-09-04

This report was submitted by a Patient from Lam, Smith and Figueroa Medical Center concerning patient ANON-PX-7824. The subject is an adult female with a significant medical history including hypertension, anxiety, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Topical route at a dosage of 104mg, initiated on 2024-07-18 for Neuropathic pain and discontinued on 2024-08-22; Metformin administered via the Oral route at a dosage of 51mg, initiated on 2024-07-18 for Type 2 diabetes and discontinued on 2024-08-22.

On approximately 2024-08-14, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Maculopapular Rash. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed north and advised arrive. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Song site factor car worry save speak ever. Just under store most return writer.</data>
report_id: ADR-2024-635
report_date: '2024-09-04'
patient_details:
  patient_id: ANON-PX-7824
  gender: Female
  relevant_history:
  - hypertension
  - anxiety
  - coronary artery disease
suspected_drugs:
- drug_name: Gabapentin
  dosage: 104mg
  route_of_administration: Topical
  start_date: '2024-07-18'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
  end_date: '2024-08-22'
- drug_name: Metformin
  dosage: 51mg
  route_of_administration: Oral
  start_date: '2024-07-18'
  indication_for_use: Type 2 diabetes
  end_date: '2024-08-22'
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2024-08-14'
  severity: Severe
  outcome: Recovered
  intervention_required: true
  intervention_details: Prescribed north and advised arrive.
- symptom_name: Maculopapular Rash
  onset_date: '2024-08-14'
  severity: Severe
  outcome: Recovering
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive rechallenge
reporting_facility: Lam, Smith and Figueroa Medical Center
reporter_type: Patient
notes: Song site factor car worry save speak ever. Just under store most return writer.
